Amgen (AMGN) Cytokinetics (CYTK) & Servier Report Start of METEORIC-HF, the Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients with Heart Failure
Tweet Send to a Friend
Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
